Literature DB >> 18159518

Complicated urinary tract infection in adults.

L E Nicolle.   

Abstract

BACKGROUND: Complicated urinary tract infection occurs in individuals with functional or structural abnormalities of the genitourinary tract.
OBJECTIVE: To review current knowledge relevant to complicated urinary tract infection, and to provide evidence-based recommendations for management.
METHODS: The literature was reviewed through a PubMed search, and additional articles were identified by journal reference review. A draft guideline was prepared and critically reviewed by members of the Association of Medical Microbiology and Infectious Disease Canada Guidelines Committee, with modifications incorporated following the review.
RESULTS: Many urological abnormalities may be associated with complicated urinary infection. There is a wide spectrum of potential infecting organisms, and isolated bacteria tend to be more resistant to antimicrobial therapy. Morbidity and infection outcomes in subjects with complicated urinary infection are principally determined by the underlying abnormality rather than the infection. Principles of management include uniform collection of a urine specimen for culture before antimicrobial therapy, characterization of the underlying genitourinary abnormality, and nontreatment of asymptomatic bacteriuria except before an invasive genitourinary procedure. The antimicrobial regimen is determined by clinical presentation, patient tolerance, renal function and known or anticipated infecting organisms. If the underlying abnormality contributing to the urinary infection cannot be corrected, then early post-treatment recurrence of infection is anticipated.
CONCLUSIONS: The management of complicated urinary infection is individualized depending on patient variables and the infecting organism. Further clinical investigations are necessary to assist in determining optimal antimicrobial regimens.

Entities:  

Keywords:  Antimicrobials; Complicated; Guidelines; Urinary infection

Year:  2005        PMID: 18159518      PMCID: PMC2094997          DOI: 10.1155/2005/385768

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  121 in total

1.  Bacteriuria in patients treated with clean intermittent catheterization.

Authors:  A Bakke; A Digranes
Journal:  Scand J Infect Dis       Date:  1991

2.  Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection.

Authors:  G J Sheehan; G K Harding; D A Haase; M J Thomson; B Urias; J K Kennedy; D J Hoban; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

3.  Comparison of netilmicin with cefoperazone for the treatment of severe or complicated urinary tract infections.

Authors:  R R Bailey; B A Peddie; K L Lynn; C P Swainson
Journal:  Aust N Z J Med       Date:  1985-02

Review 4.  Bacterial urinary tract infections in diabetes.

Authors:  J E Patterson; V T Andriole
Journal:  Infect Dis Clin North Am       Date:  1997-09       Impact factor: 5.982

5.  Accuracy of rapid urine screening tests among incontinent nursing home residents with asymptomatic bacteriuria.

Authors:  J G Ouslander; M Schapira; S Fingold; J Schnelle
Journal:  J Am Geriatr Soc       Date:  1995-07       Impact factor: 5.562

6.  Molecular typing and fluconazole susceptibility of urinary Candida glabrata isolates from hospitalized patients.

Authors:  U Schwab; F Chernomas; L Larcom; J Weems
Journal:  Diagn Microbiol Infect Dis       Date:  1997-09       Impact factor: 2.803

7.  Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial.

Authors:  J Sifuentes-Osornio; E Jakob; L Clara; R Durlach; A Dain; G M Ruìz-Palacios; L Barkan; R Lamberghini; A Jáuregui; Y Villalobos; C Sáenz-Aguirre; F J de la Cabada; A Rodríguez-Toledo; I Zavala-Trujillo; M A Gamboa; S Fuentes del Toro; C Froiler; F Maglio; J V Quiroga; J J Rojas; I Conde-Carmona
Journal:  J Chemother       Date:  1996-04       Impact factor: 1.714

8.  Outcome following antimicrobial therapy for asymptomatic bacteriuria in elderly women resident in an institution.

Authors:  L E Nicolle; J W Mayhew; L Bryan
Journal:  Age Ageing       Date:  1988-05       Impact factor: 10.668

9.  Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women.

Authors:  L E Nicolle; W J Mayhew; L Bryan
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

10.  Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective, randomized, comparative study.

Authors:  K Pummer
Journal:  Am J Med       Date:  1993-03-22       Impact factor: 4.965

View more
  63 in total

1.  Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial.

Authors:  Jutta Bleidorn; Ildikó Gágyor; Michael M Kochen; Karl Wegscheider; Eva Hummers-Pradier
Journal:  BMC Med       Date:  2010-05-26       Impact factor: 8.775

2.  Differential characteristics of healthcare-associated compared to community-acquired febrile urinary tract infections in males.

Authors:  A Smithson; J Ramos; M T Bastida; S Bernal; N Jove; E Niño; N Msabri; R Porrón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-25       Impact factor: 3.267

3.  Complicated pyelonephritis: unresolved issues.

Authors:  Lindsay E Nicolle
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

Review 4.  Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.

Authors:  Krishan P Singh; Gang Li; Fanny S Mitrani-Gold; Milena Kurtinecz; Jeffrey Wetherington; John F Tomayko; Linda M Mundy
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

5.  Propensity-matched analysis to compare the therapeutic efficacies of cefuroxime versus cefotaxime as initial antimicrobial therapy for community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae infection in women.

Authors:  U-Im Chang; Hyung Wook Kim; Seong-Heon Wie
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

6.  Advances in management of urinary tract infections.

Authors:  Syed Ahmed Zaki; Baldev S Prajapati
Journal:  Indian J Pediatr       Date:  2010-02       Impact factor: 1.967

7.  The role of host factors and bacterial virulence genes in the development of pyelonephritis caused by Escherichia coli in renal transplant recipients.

Authors:  Priscila Reina Siliano; Lillian Andrade Rocha; José Osmar Medina-Pestana; Ita Pfeferman Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-06       Impact factor: 8.237

8.  Antimicrobial resistance in community-acquired Escherichia coli isolated from urinary infection: Good news or bad?

Authors:  Lindsay E Nicolle
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Authors:  Sherwin K B Sy; Luning Zhuang; Serubbabel Sy; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

10.  Exploring the Effectiveness of Team-based Enablement Interventions to Improve Antibiotic Prescribing within a Psychiatric Hospital.

Authors:  Emily E Leppien; Tammie Lee Demler; Eileen Trigoboff
Journal:  Innov Clin Neurosci       Date:  2019-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.